CARDIORISC - Key Persons
Job Titles:
- Senior Lecturer in Stratified Medicine
Job Titles:
- Postdoctoral Research Associate
Job Titles:
- Lecturer in Computational Biology
Job Titles:
- Lecturer in Cellular Ageing
Job Titles:
- Lecturer
- Fellow of the Higher Education Academy
- Lecturer in Stratified Medicine
is a Lecturer in Personalised Medicine with an interest in the inflammatory aspects of cardiovascular disease. Dr McGilligan is the academic lead for the Cardiovascular Research and Improvement Science Centre (CardioRISC). This centre originates from Northern Ireland Centre for Stratified Medicine (NICSM), at the C-TRIC research site of Altnagelvin hospital. CardioRISC was set up to IMPROVE Cardiovascular Health through the integration of Digital Cardiology and Personalised Medicine. Dr McGilligan's research focuses on the development of novel biological therapeutics for coronary artery disease and other inflammatory diseases. She is inventor of IntraCell a drug delivery technology for larger molecules. She previously worked for industrial and pharmaceutical companies in the areas of therapy and point of care test development. Victoria completed a postdoctoral training fellowship at Harvard Medical School and was awarded the Cora Verhagen Immunology prize for presentation of her findings there in relation to the NLRP3 Inflammasome. This key regulator of the immune system is still a focus of Victoria's work and is central to PhD projects which she supervises.
Current clinical research projects led by Dr McGilligan involve the recruitment of 1200 CVD patients to investigate novel biomarkers and algorithms to predict disease risk. Additionally she is PI for a project that aims to better stratify patients undergoing CT angiography using machine learning approaches combined with 3D modelling.
She currently supervises two PhD students working on computational cardiovascular projects. The first aims to improve clinical decision making and patient safety by improving electrocardiogram interpretation and the second aims to develop novel health informatics systems to improve triage of patients for ST-Elevated Myocardial Infarction.
Her teaching duties include co-ordinating the Inflammatory and Immunological disease undergraduate module in personalised medicine. She also co-ordinates two modules on the postgraduate personalised medicine course; Clinical Trial Design and Patient Recruitment and the Clinical Governance and Research Ethics modules.
She has published her research works in leading journals across several fields and has mentored several postdoctoral researchers and Ph.D. students working on cardiovascular and other related research projects, which are supported by multiple research grants (as PI or Co-I) including those sponsored by industry and European funding.
She is inventor of several diagnostic/therapeutic products with several invention disclosures and 3 patents currently filed. Victoria is founder of Athlas therapeutics a new start up company which focuses on the development of biological therapeutics for inflammatory disease.
Victoria McGilligan is a Lecturer in Personalised Medicine with an interest in the inflammatory aspects of cardiovascular disease. Dr McGilligan is the academic lead for the Cardiovascular Research and Improvement Science Centre (CardioRISC). This centre originates from Northern Ireland Centre for Stratified Medicine (NICSM), at the C-TRIC research site of Altnagelvin hospital. CardioRISC was set up to IMPROVE Cardiovascular Health through the integration of Digital Cardiology and Personalised Medicine. Dr McGilligan's research focuses on the development of novel biological therapeutics for coronary artery disease and other inflammatory diseases. She is inventor of IntraCell a drug delivery technology for larger molecules. She previously worked for industrial and pharmaceutical companies in the areas of therapy and point of care test development. Victoria completed a postdoctoral training fellowship at Harvard Medical School and was awarded the Cora Verhagen Immunology prize for presentation of her findings there in relation to the NLRP3 Inflammasome. This key regulator of the immune system is still a focus of Victoria's work and is central to PhD projects which she supervises.
Invest NI. V McGilligan. Development of a novel inhibitor for inflammatory disease. Nov 2018 - Dec 2021. £154k
Victoria is a fellow of the Higher Education Academy. She currently serves as lecturer on the BSc and MSc degrees in Personalised Medicine.